Neoleukin Therapeutics Inc (NAS:NLTX)
$ 3.49 0 (0%) Market Cap: 8.20 Mil Enterprise Value: -35.02 Mil PE Ratio: 0 PB Ratio: 0.10 GF Score: 22/100

Capricor Therapeutics Inc To Present 18-Month Data Results From Ongoing HOPE-2 Open Label Extension Transcript

Jan 25, 2023 / 06:00PM GMT
Release Date Price: $12.2 (+3.36%)
Pat Furlong
Parent Project Muscular Dystrophy - Moderator

Hi. Good afternoon, and welcome to PPMDs webinar with Capricor Therapeutics. I'm Pat Furlong, and I'm going to be joining the webinar with Linda Marbán and Dr. Craig McDonald. We're here today to talk about CAP-1002 programs in HOPE-1 and HOPE-2 and bring up to date on recruiting for this Phase 3 program.

So with that, I'm going to turn the slides over to Linda and Dr. Craig McDonald. Please begin. (Conference Instructions) Thank you for joining us, Linda?

Linda MarbÃ;n
Capricor Therapeutics, Inc. - CEO & Director

¡ -

Thank you, Pat. And thank you, PPMD, for giving us this opportunity to provide this update to the community. This webinar primarily focusses on patients and their families to allow you to see the long-term benefits of CAP-1002 in those boys and young men that were in the HOPE-2 enter the HOPE-2 open-label extension trial.

Next slide, please, AJ. We are a publicly traded company. Our symbol is CAPR. And all of our filings are up to date with the SEC,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot